BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 4119363)

  • 1. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
    Glae GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    J Natl Cancer Inst; 1976 Dec; 57(6):1363-6. PubMed ID: 187805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
    [No Abstract]   [Full Text] [Related]  

  • 6. Antileukemic properties of organoplatinum complexes.
    Meischen SJ; Gale GR; Lake LM; Frangakis CJ; Rosenblum MG; Walker EM; Atkins LM; Smith AB
    J Natl Cancer Inst; 1976 Oct; 57(4):841-5. PubMed ID: 1003531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs on the horizon in bronchogenic carcinoma.
    Carter SK
    Cancer; 1972 Nov; 30(5):1402-9. PubMed ID: 4117256
    [No Abstract]   [Full Text] [Related]  

  • 8. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM; Helfman D
    Cancer Res; 1976 Dec; 36(12):4434-8. PubMed ID: 1000492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: ICRF 159.
    Bellet RE; Mastrangelo MJ; Dixon LM
    Lancet; 1974 May; 1(7863):926. PubMed ID: 4133440
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic effects of the combination of cis-platinum diamminodichloride and 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in transplanted mouse leukemias.
    Burchenal JH; O'Toole T; Kalaher K; Chisholm J
    Cancer Res; 1977 Nov; 37(11):4098-100. PubMed ID: 71204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
    Walker EM; Gale GR
    Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia.
    Burchenal JH; Kalaher K; O'Toole T; Chisholm J
    Cancer Res; 1977 Sep; 37(9):3455-7. PubMed ID: 884687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New cancer chemotherapeutic agents.
    Burchenal JH; Carter SK
    Cancer; 1972 Dec; 30(6):1639-46. PubMed ID: 4118405
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 16. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of cyclocytidine in a variety of tumors.
    Hoshi A; Kanzawa F; Kuretani K
    Gan; 1972 Jun; 63(3):353-60. PubMed ID: 5072834
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.